Breast Cancer
9
Companies
13
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Rigel Pharmaceuticals
Veppanu
AstraZeneca
Enhertu
Roche Holding AG
trastuzumab (Herceptinยฎ)
Eli Lilly and Company
Abemaciclib
INTENSITY THERAPEUTICS, INC.
INT230-6
MERCK
Lonafarnib
Marker Therapeutics, Inc.
Low dose FRฮฑ vaccine
PUMA BIOTECHNOLOGY, INC.
Temsirolimus
Arvinas, Inc.
ARV-471
Roche Holding AG
Trastuzumab, Docetaxel
Merck
pembrolizumab
Astrazeneca
capivasertib
Roche
giredestrant
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Veppanu | Approved | โ | โ | โ |
| AZN AstraZeneca | Enhertu | Approved | โ | โ | โ |
| RHHBY Roche Holding AG | trastuzumab (Herceptinยฎ) | Phase 3 | โ | โ | โ |
| LLY Eli Lilly and Company | Abemaciclib | Phase 3 | โ | โ | โ |
| INTS INTENSITY THERAPEUTICS, INC. | INT230-6 | Phase 3 | โ | โ | โ |
| MRK MERCK | Lonafarnib | Phase 2 | โ | โ | โ |
| MRKR Marker Therapeutics, Inc. | Low dose FRฮฑ vaccine | Phase 2 | โ | โ | โ |
| PBYI PUMA BIOTECHNOLOGY, INC. | Temsirolimus | Phase 2 | โ | โ | โ |
| ARVN Arvinas, Inc. | ARV-471 | Phase 2 | โ | โ | โ |
| RHHBY Roche Holding AG | Trastuzumab, Docetaxel | Phase 2 | โ | โ | โ |
| MRK Merck | pembrolizumab | โ | โ | โ | โ |
| AZN Astrazeneca | capivasertib | โ | โ | โ | โ |
| RHHBY Roche | giredestrant | โ | โ | โ | โ |
Not financial advice
Signals are probabilistic and based on historical data โ past performance doesn't guarantee future results. Do your own research.